Authors: Li X, Yang X, Zhou Y, Wang S, Chen X.
DOI: 10.3389/fcvm.2025.1672940
Abstract Summary
New research suggests hypertensive patients with heart failure may safely start β-blockers at higher initial doses than current guidelines recommend. A study of 307 patients found no increased risk of adverse effects like bradycardia or hypotension with high-dose initiation, challenging the standard “start low, go slow” approach.
Why Brain? 🧠
Study shows hypertensive heart failure patients safely tolerate higher initial β-blocker doses than current guidelines recommend, potentially allowing faster optimization of this cornerstone therapy.
License: cc by.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
